Intravenous steroid ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04106830 (ClinicalTrials.gov)	January 1, 2019	25/9/2019	Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)	Prospective Cohort Study of Clinical and Imaging Patterns of Neuroinflammation Diseases (CLUE)	NMO Spectrum Disorder;MRI;Multiple Sclerosis	Drug: Intravenous steroid	Beijing Tiantan Hospital	NULL	Recruiting	16 Years	80 Years	All	1000		China
2	NCT01411514 (ClinicalTrials.gov)	August 2011	26/5/2011	Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis	Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort	Multiple Sclerosis	Drug: Prednisone;Drug: Placebo	Claudio Gobbi	Ente Ospedaliero Cantonale, Ticino, Switzerland	Terminated	18 Years	80 Years	Both	27	Phase 4	Switzerland